Health Insights

The factors that trigger cellular carcinogenesis can generally be divided into two categories: (1) uncontrollable factors, such as inherited DNA from family, infections with known viruses including hepatitis C virus (HCV), hepatitis B virus (HBV), human papillomavirus (HPV), and Epstein-Barr virus (EBV); (2) controllable factors, such as avoiding prolonged exposure to chemical carcinogens (through inhalation, skin contact, or ingestion), maintaining strong immunity, and preventing chronic inflammation. Chronic inflammation produces excess free radicals that can damage cellular DNA and cause mutations. Excessive stress can also suppress or alter the immune recognition system. Numerous studies have shown that cancer, diabetes, hypertension, immune disorders, and many unexplained diseases are caused by chronic inflammation. Therefore, completely preventing cancer is difficult; only controllable factors can be managed to reduce risk.

The human body is naturally equipped with self-protection mechanisms. When a cell’s DNA mutation cannot be repaired, apoptosis (programmed cell death) is triggered, allowing the mutated cell to be eliminated. However, during cancer progression, this apoptotic mechanism is often disabled, so mutated cancer cells do not self-destruct, resulting in uncontrolled growth and tumor formation. Modern imaging equipment can detect tumors of approximately 0.5–1.0 cm, which may contain roughly 10⁷–10⁹ cancer cells. People often react to abnormal cells with aggressive measures, unaware that these cancer cells originated from their own normal cells. Cancer cells are more resilient than normal cells, and chemotherapy drugs cannot distinguish between normal and abnormal cells. Aggressive chemotherapy can therefore cause significant suffering while cancer cells may develop drug resistance. Treating cancer is challenging. Precision medicine now targets dominant cancer genes with specific drugs or combines therapies to effectively kill cancer cells. DEYING Pharmaceutical’s approach focuses on regulating cancer cell gene mechanisms to restore apoptotic functions in previously resistant cells. This strategy aims to selectively kill cancer cells without harming normal cells and to reduce cancer cell drug resistance, enhancing chemotherapy efficacy, potentially leading to significant breakthroughs in cancer treatment.

Not all human diseases have effective medications. For example, liver cirrhosis, kidney failure, and dialysis have no direct drug treatment. However, the liver is the only organ in the body capable of regeneration; with a healthy liver environment, it can self-heal. The challenge in treating liver cirrhosis lies in the lack of effective drugs to remove the causative factors. Recently, COVID-19 has highlighted that even with vaccination, infected individuals exhibit widely varying symptoms—some are asymptomatic, some test positive for viral RNA but are not infectious, some have mild symptoms, while others face life-threatening complications. The key factor is liver function. The liver serves as the body’s first-line immune organ and is the largest reticuloendothelial phagocytic system. Its blood vessels are populated with Kupffer cells, specialized immune cells that immediately engulf and destroy invading bacteria or viruses. When the invasion overwhelms these cells, a second-line defense involving interferons, natural killer cells, and antibodies is activated to combat the pathogens.

Silymarin is a globally recognized hepatoprotective compound, with over 4,000 published academic papers demonstrating its benefits, including liver and kidney protection, antiviral effects, immune regulation, mitigation of chemotherapy-induced damage, reduction of diabetes-related chronic nephrotoxicity, improvement of fatty liver, and reduction of liver inflammation. However, oral silymarin has low bioavailability, resulting in unclear efficacy. Currently, only Germany, Taiwan, and China regulate it as a drug; in other countries, including the U.S., it is marketed as a dietary supplement. To ensure drug efficacy, the U.S. Pharmacopeia and Taiwan’s latest eighth edition of the Chinese Pharmacopeia require silymarin to achieve a minimum dissolution and absorption rate of 75% under simulated gastrointestinal conditions. Analysis of commercially available silymarin products in the U.S., Germany, Japan, and Taiwan shows that only the original German formulation and Taiwan DEYING Pharmaceutical’s silymarin liver drug fully meet pharmacopeial standards. Moreover, DEYING Pharmaceutical’s silymarin achieves 98% bioavailability, far exceeding the German original at 78%, making it the world’s leading liver medicine with significant benefits for treating liver, gallbladder, and kidney diseases.